Abstract
The SARS-CoV-2 (COVID-19) pandemic has particularly serious consequences for cancer patients, as they are at high risk for severe complications and mortality due to the virus since cancer patients are immunocompromised. Preliminary evidence suggests that patients with hematological, and metastatic malignancies are particularly susceptible to developing severe COVID-19 illness, which leads to poor prognosis. Biomarkers including C-reactive protein and interleukin-6 may be predictors of outcome and, therefore, crucial in assessing COVID-19 illness severity in cancer patients. A patient-specific risk and benefit inventory should be completed, and expert guidelines consulted when deciding to continue or postpone therapeutic interventions. This review presents preliminary evidence of COVID-19 infection and its impact on cancer, as well as discussion of general guidelines for the treatment and management of cancer patients with COVID-19.
Keywords: Biomarkers; C-reactive protein; Covid-19; Interleukin-6; Sever acute respiratory syndrome coronavirus 2.
【저자키워드】 COVID-19, Biomarkers, interleukin-6, C-reactive protein, Sever acute respiratory syndrome coronavirus 2., 【초록키워드】 Treatment, SARS-CoV-2, coronavirus, pandemic, Biomarkers, Mortality, severity, Cancer, interleukin-6, C-reactive protein, risk, outcome, virus, interleukin, COVID-19 infection, management, Patient, Cancer patients, Immunocompromised, predictor, respiratory, Evidence, malignancy, high risk, cancer patient, leads, evidence of, acute respiratory syndrome, acute respiratory syndrome coronavirus, poor prognosis, COVID-19 illness, therapeutic interventions, hematological, malignancies, severe complications, preliminary evidence, severe COVID-19 illness, susceptible, benefit, consequence, severe complication, with COVID-19, 【제목키워드】 Patient, complications,